stent types are similar. CSs are associated with an increased risk of postoperative acute limb ischemia and subsequent open revascularization.
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Exploring Objectives: Sleep disturbance is an important determinant of both physical and mental health plus quality of life (QOL). Sleep disturbance associated with subclinical cardiovascular disease has been described, but associations with symptomatic peripheral artery disease (PAD) are unknown. We prospectively studied sleep disturbance among patients with symptomatic PAD over 30 days using wearable devices.
Methods: Claudicant patients with an ankle-brachial index <.9 were recruited and received walking exercise instructions, a wearable device to track walking and sleep, and access to a PAD-specific digital health platform with educational materials, online communities, and surveys. Participants set walking goals, received weekly phone follow-up, and completed pre/post QOL instruments (Walking Impairment Questionnaire and VascuQol-6). Associations between sleep interruption, walking, patient characteristics, and survey responses were evaluated using Poisson regression. Results: A total of 20 participants (35% women, 30% African American; mean age, 69 6 9 years) enrolled and completed the study. Mean anklebrachial index was 0.69 6 0.14. Over a mean study period of 34 6 6 days, sleep data were recorded an average of 28 6 6 days and walking activity on 12 6 10 days. Mean nights of interrupted sleep were 1.3 6 1.8, and eight participants (40%) had sleep interruption at least one night. Sleep disturbance was associated with higher (more severe) Walking Impairment Questionnaire speed (P ¼ .002), distance (P ¼ .030), and overall (P ¼ .009) scores. No associations between sleep disturbance and daily walking or VascuQol-6 scores were observed.
Conclusions: Sleep disturbance impacts walking, disability and QOL among people with symptomatic PAD. Ongoing investigations will further characterize sleep disturbance among patients with claudication as well as critical limb ischemia, evaluate associations with disease severity, and explore the utility of sleep end points as a PAD treatment outcomes. Objectives: The role of catheter-directed thrombolysis (CDT) in the treatment of acute lower extremity ischemia may require prolonged periods of time to achieve successful lysis. Prolonged thrombolysis infusion has demonstrated increased incidence of intracranial bleeding, stroke, and local complications. It is expensive and increases hospital length of stay. To minimize these potentially negative outcomes, we developed a fast track approach (FTA) that included the use of aggressive balloon angioplasty and stenting before the thrombus was completely lysed. The goal of FTA is to restore arterial patency during the first procedure, thus eliminating the need for repeated thrombolysis procedures.
Methods: This was a retrospective review of 26 consecutive patients treated with FTA from January 2014 to August 2016. The FTA protocol included an angiogram of the inflow and outflow vessels as well as segmentally alongside the occluded segment. This was followed by intraclot infusion of thrombolytic agent and percutaneous mechanical thrombectomy (AngioJet system). Next, balloon angioplasty of the remaining occluded segment (s) and stenting in case of recoil, as shown during deflation and reinflation of the angioplasty balloon (waist), were performed.
Results: There were 36 procedures performed in 26 patients (61% females). The median age was 63 years (range, 41-98 years). The indication for lytic therapy was acute in-stent occlusion in the femoral-popliteal segment. The treatment was directed toward the left lower extremity in 52.8% of the procedures. Comorbidities included hypertension, diabetes mellitus, and hypercholesterolemia in 28%, 14%, and 16% of patients, respectively. The average operating room time was 123 minutes (range, 70-385 minutes), and the median total alteplase and heparin infusion per procedure was 10 mg (range, 4-30 mg) and 8000 units (range, 6000-10000 units), respectively. The median cost with interventional tools and medications was $4673.19 per procedure. Median postoperative length of stay was 2 days (range, 1-25 days). Successful FTA, as defined by widely patent inflow and outflow at discharge without a need for second intervention, occurred in 80.6% (29 of 36 cases). Periprocedural complications included one patient who required blood transfusion for retroperitoneal bleeding and one patient with a postoperative fever that resolved. No deaths, limb loss, pulmonary embolism, myocardial infarction, intracranial hemorrhage, or compartment syndrome occurred in this series immediately after FTA.
Conclusions: These preliminary data suggest that an aggressive approach at balloon angioplasty and stenting prior to complete lysis of the thrombotic event can generate acceptable results and minimize complications related to prolonged thrombolytic therapy.
Author Disclosures: E. Ascher: Nothing to disclose; A. Hingorani: Nothing to disclose; N. Marks: Nothing to disclose; S. Rizvi: Nothing to disclose.
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A Matched Case-Control Study on Open and Endovascular Treatment of Popliteal Artery Aneurysms
Walter Dorigo, Fabrizio Masciello, Giulia Bassoli, Alessandro Alessi Innocenti, Aaron Fargion, Rossella Di Domenico, Alberto Melani, Carlo Pratesi. University of Florence, Florence, Italy
Objectives: This study compared early and late results of open and endovascular management of popliteal artery aneurysm (PAA) in a retrospective single-center matched case-control study.
Methods: From January 1981 to December 2015, 309 consecutive interventions for PAA were performed in our institution. Data concerning these interventions were prospectively inserted in a dedicated database. A retrospective analysis of such database was performed, and 59 interventions carried out with endovascular repair (ER) were found, while the remaining 250 intervention were open repair (OR). ER was preferred in older asymptomatic patients, while OR was offered more frequently to patients with a thrombosed PAA and a poor run-off status. A one-to-one coarsened exact matching on the basis of all the baseline demographic, clinical and anatomical covariates significantly different between the two treatment options was performed, and two equivalent groups of 56 ERs and ORs were generated. The two groups were compared in terms of perioperative (<30 days) results with c 2 test and of follow-up outcomes with Kaplan-Meier curves and log-rank test.
Results: There were no differences between the two groups in perioperative deaths, thromboses, and amputations. The 30-day amputation and death rate was 2% in ER group and 5% in OR group (P ¼ .3). Follow-up was available for 108 patients (96.5% of the study group) with a mean duration of 53 months, significantly different in the two groups (71 months in OR group and 36 months in ER group; P < .001). Estimated 4-year survival rates were 89% (standard error [SE] , 0.055) in OR patients and 94% (SE, 0.08) in ER patients (P ¼ .4; log-rank, 0.7). At the same time interval, primary patency rates were 72% (SE, 0.06) in ER group and 75% (SE, 0.07) in OR group (P ¼ .9; log-rank, 0.01). Twentytwo PAA-related reinterventions were performed during follow-up, 11 in each group. Estimated 4-year freedom from reintervention was 85% (SE, 0.06) in OR patients and 66% (SE, 0.08) in ER patients (P ¼ .1; logrank, 2.1). Secondary patency rates at 48 years were 75% (SE, 0.08) in ER group and 83% (SE, 0.055) in OR group (P ¼ .9; log-rank, 0.02), while the corresponding figures in terms of limb preservation was 94% in both groups (P ¼ .4, log-rank, 0.9), respectively.
Conclusions: OR and ER of PAAs provided in this retrospective singlecenter experience similar perioperative and follow-up results in equivalent groups of patients. There is a trend toward a higher risk of reintervention in ER patients, requiring further analysis and a longer follow-up time.
